Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    NCT01149083
Show Display Options
Rank Status Study
1 Active, not recruiting Veliparib With or Without Carboplatin in Treating Patients With Stage III-IV Breast Cancer
Conditions: BRCA1 Mutation Carrier;   BRCA2 Mutation Carrier;   Recurrent Breast Carcinoma;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: Carboplatin;   Other: Laboratory Biomarker Analysis;   Drug: Veliparib

Indicates status has not been verified in more than two years